Annovis Bio
ANVS | NYSE
$0.76
-$0.17 (-17.94%)
At close: Nov 16, 2026, 3:59 PM ET
$0.78
+$0.02 (+2.63%)
After-hours:
Nov 16, 2026, 7:36 PM ET
Annovis Bio Company Profile
Company profile explainedCompany Profile
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Maria L. Maccecchini | Founder, Acting CFO, CEO, President & Executive Director |
| Blake Jensen | Head of Quality |
| Cheng Fang | Chief Scientific Officer |
| Eve Damiano | Senior Vice President of Regulatory Operations |
| Hilda Maibach | Senior Vice President of Statistics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 8-K | Current Report |
| Oct 20, 2026 | 8-K | Current Report |
| Oct 15, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 07, 2026 | DEFA14A | Filing |
| Sep 11, 2026 | DEF 14A | Filing |
| Aug 25, 2026 | PRE 14A | Filing |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 29, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Annovis Bio
| Country | United States |
| IPO Date | Jan 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Maria L. Maccecchini |
Contact Details
101 Lindenwood Drive Malvern,
Pennsylvania 19355 United States
Stock Details
| Ticker Symbol | ANVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001477845 |
| CUSIP Number | 03615A108 |
| ISIN Number | US03615A1088 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ANVS